by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
Modified CALR Mutation helps Identify New Drug Targets for MPN Cancer
Summary The research article discusses myeloproliferative neoplasms (MPN), a type of cancer that affects the blood and bone marrow. It focuses on the Calreticulin (CALR) mutation found in 20% to 25% of MPN patients (with ET and MF) and, which is a potential target for new drug therapies. The authors describe a novel approach using […]